Summary
Client: IQVIA Solutions Canada Inc.
Project ID: P2022-122A / 2023 0970 328 000
Research Question/Objectives: Hemoglobinopathies represent a group of lifelong, autosomal recessive genetic disorders that affect the structure or production of hemoglobin (Hb) molecule. Sickle cell disease (SCD) is a group of hemoglobinopathies characterized by a “sickle shaped” hemoglobin (HbS). Vaso-occlusive crises (VOC) are severe painful events that constitute the hallmark clinical feature of SCD, and are the leading cause of emergency department visits and hospitalizations for affected patients. Describing the treatment patterns, disease progression and healthcare resources utilization of patients with SCD will provide valuable evidence on the clinical and economic implications of SCD in Canada.
Feasibility Study Objectives
Phase 1:
- Identify sample sizes of SCD cohort
- Identify sample sizes of SCD patients with recurrent VOCs sub-group
Phase 2:
- Describe baseline characteristics of cohorts and sub-groups
- Describe acute and chronic complications of cohorts and sub-groups
- Describe treatment patterns of cohorts and sub-groups
Status: Completed
Results: March 2025